High-Resolution Mapping of Human Chromosome 11 by in Situ Hybridization with Cosmid Clones

Lichter, Peter; Tang, Chieh-Ju C.; Call, Katherine M.; Hermanson, Gary; Evans, Glen A.; Housman, David E.; Ward, David C.

doi:10.1126/science.2294592

Cited by 1,267 publications

(606 citation statements)

References 46 publications

Supporting

Mentioning

592

Contrasting

Unclassified

Order By: Relevance

“…Fluorescence in situ hybridization (FISH) on DAPI banded metaphase chromosomes (Schweizer and Ambros, 1994) from two normal, healthy donors (male and female) was performed by a modi®cation of the protocols of (Lichter et al, 1990). Cells were harvested and slides prepared according to standard cytogenetic techniques.…”

Section: In Situ Hybridizationmentioning

confidence: 99%

Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma

et al. 1999

View full text Add to dashboard Cite

Section: In Situ Hybridizationmentioning

confidence: 99%

Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma

et al. 1999

View full text Add to dashboard Cite

“…Archival cytological smears stained with PAP or MGG were destained and treated before in situ hybridization, essentially according to Cajulis et al (1996). The biotinylated probe p53 (TP53) (Oncor, Gaithersburg, MD, USA) was cohybridized with the digoxigenin-labelled chromosome 17 a-satellite (D17Z1) (Oncor) according to Lichter et al (1990) and the manufacturer's recommendations. The biotinylated probe p53 was detected by two layers of avidin-FITC (Vector), and chromosome 17 a-satellite by one layer of rhodamine-labelled anti-digoxigenin (ab) (Boehringer Mannheim).…”

Section: Dna Analysismentioning

confidence: 99%

Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma

Lavarino

Corletto²,

Mezzelani³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary Recent preclinical and clinical data suggest that TP53 status and TP53 mutations may be important in determining tumour aggressiveness and therapy response. In this study we investigate the feasibility of a structural and quantitative analysis of TP53 on fineneedle aspiration (FNA) material obtained from 31 consecutive female patients with breast carcinoma, enrolled in a primary chemotherapy protocol. Tumours were screened for p53 protein overexpression and TP53 mutations (exons 5-8) using immunocytochemistry, polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and DNA sequencing analyses, and finally using fluorescence in situ hybridization (FISH) analysis. Positive nuclear staining was identified in six cases whereas mutations were detected in nine. Although the immunoreactive pattern fitted fully with the characterized TP53 mutation type, the considerable number of null p53 mutations (i.e. four) coupled with the lack of information regarding the localization of TP53 mutations make immunocytochemistry an inadequate indicator of TP53 function deregulation. Combining molecular and FISH analyses, we detected three cases with TP53 deletion and one case with deletion and mutation. Finally, DNA static-image analysis performed on 29 cases showed aneuploidy in 26 cases, which included all TP53-mutated cases. The present results show that FNA may assist clinical decisions by allowing the evaluation of a variety of biological parameters relevant for prognosis and treatment planning.Keywords: fine-needle aspiration; breast carcinoma; TP53 analysis; fluorescence in situ hybridization analysis; DNA content analysisThe fine-needle aspiration (FNA) technique represents one of the most effective and versatile methodologies that contribute to the diagnosis and the management of breast cancer. Over recent years, the field of FNA application has expanded, and currently FNA spans the diagnostic assessment of palpable and non-palpable nodules and contributes to management decisions at surgical and medical levels (Masood et al, 1990;Layfield, 1992). In fact, FNA has largely replaced frozen sections and, in cases candidated to primary chemotherapy, provides hormonal receptor assessment as well as other useful pathobiological parameters with an efficiency that equals that of histology (Thomas et al, 1990;Dowell et al, 1994;Leong et al, 1996).Recent clinical evidence supports a critical role of TP53 status in providing prognostic information (Kovach et al, 1996;Sjogren et al, 1996). Preclinical (Lowe et al, 1993 Wahl et al, 1996) and clinical data (Bergh et al, 1995; Aas et al, 1996;Fricker, 1996;Sjogren et al, 1996) suggest that TP53 status and TP53 mutation types may be important not only in determining tumour aggressiveness but also in the response to therapy. In fact, there is increasing evidence that tumours lacking normal TP53 function are clinically more aggressive as they acquire a selective growth advantage becoming more resistant to ionizing radiations and some widely used anti-cancer drugs...

show abstract

“…The cosmid DNA from candidate clones was labeled with biotin-14-dATP (BRL) by nick-translation, as described previously (Lichter et al, 1990). The labeled DNA was denatured at 75~ for 5 rain, and preannealed with human Cot-1 DNA (BRL) at 37~ for 30 min.…”

Section: Isolation Of Genomic Clones For Human Chymotrypsinogen Genementioning

confidence: 99%

Genomic cloning and partial characterization of human chymotrypsinogen gene

et al. 1993

View full text Add to dashboard Cite

SummaryChymotrypsinogen is a principal precursor of pancreatic proteolytic enzymes. We previously isolated a cDNA clone for human prechymotrypsinogen from a human pancreatic cDNA library. In the present study, we used this cDNA sequences to isolate genomic DNA clones. Three overlapping cosmid clones spanning approximately 65-kb genomic sequences were isolated from a human cosmid library. The genomic DNA clones were characterized by restriction enzyme mapping and by hybridizing them to subfragments of the cDNA. The sequence tagged sites for human chymotrypsinogen gene were created by designing two oligonucleotides. Furthermore, the isolated genomic clones were confirmed to be localized on chromosome 16q23 by fluorescence in situ hybridization and G-banding analysis.

show abstract

High-Resolution Mapping of Human Chromosome 11 by in Situ Hybridization with Cosmid Clones

Cited by 1,267 publications

References 46 publications

Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma

Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma

Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma

Genomic cloning and partial characterization of human chymotrypsinogen gene

Contact Info

Product

Resources

About